Pharming To Participate In HAE Panel At 10th Annual BIO CEO & Investor Conference

Leiden, Netherlands, Feb 7, 2008 - (ABN Newswire) - Leiden, The Netherlands, February 6, 2008. Biotech company Pharming Group NV ("Pharming") (NYSE Euronext: PHARM) today announced that it will participate in the therapeutic workshop on Hereditary Angioedema (HAE) at the BIO CEO & Investor Conference 2008 (February 11-13, 2008) in New York.

Samir Singh, President US Operations of Pharming, is one of the panellists of the HAE panel "Who's on First?" The workshop will cover the unmet medical need in HAE, therapeutic options in development and the commercial market opportunity. The workshop is scheduled for Monday, February 11, 2008 at 9:30 am Eastern Time at the Waldorf Astoria Hotel in New York City, NY.

The BIO CEO & Investor Conference is attended by institutional investors, industry analysts and senior biotechnology executives and focuses on biotech investment opportunities. For further information on the conference, please visit ceo.bio.org/. More information on the HAE workshop can be found on ceo.bio.org/opencms/ceo/2008/program/focusSessionDetails.jsp?id=342

About Rhucin® and HAE Rhucin® (recombinant human C1 esterase inhibitor) is a human protein developed through Pharming's proprietary technology where the human protein is expressed in milk of transgenic rabbits. Rhucin® is currently under development for treatment of patients with acute attacks of Hereditary Angioedema (HAE). HAE is a human genetic disorder caused by a shortage of C1 inhibitor activity and results in an overreaction of the immune system. The disease is characterized by acute attacks of painful and in some cases fatal swelling of several soft tissues (edema), which may last up to five days when untreated.

About Pharming Group NV Pharming Group NV is developing innovative products for the treatment of genetic disorders, ageing diseases, specialty products for surgical indications, intermediates for various applications and nutritional products. Pharming has two products in late stage development - Rhucin® (recombinant human C1 inhibitor) for Hereditary Angioedema and human lactoferrin for use in food products. The advanced technologies of the Company include innovative platforms for the production of protein therapeutics, technology and processes for the purification and formulation of these products, as well as technologies in the field of tissue repair (via its collaboration with NovaThera) and DNA repair (via DNage). Additional information is available on the Pharming website: www.pharming.com and on www.dnage.nl.

This press release contains forward looking statements that involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company to be materially different from the results, performance or achievements expressed or implied by these forward looking statements. The press release also appears in Dutch. In the event of any inconsistency, the English version will prevail over the Dutch version.

Contact: Carina Hamaker, Investor Voice (NL), T: +31 (0)6 537 499 59 Julia Philips, Financial Dynamics (UK), T: +44 (0)20 7269 7187 or +44 (0)7747 602 739 Samir Singh, Pharming Group NV (US), T: +1 908 720 6224 Rein Strijker, Pharming Group NV, T: +31 (0)71 52 47 400



LINK: http://hugin.info/132866/R/1189131/238992.pdf

Copyright © Hugin AS 2008. All rights reserved.

Pharming Group N.V.

http://www.pharming.com

ISIN: NL0000377018

Stock Identifier: AEX.PHARM

US: PINKSHEETS: PHGUF